Member Info for troutisout

Orbiter, The PSAwatch is a point of care test for PSA, it is not as such a test for prostate cancer, but is one of several different factors that can lead a doctor to want to investigate more. Most PSA tests are lab based and take a much longer turnaround, this test gives a result in 10 minutes and can be performed by a clinic nurse. A fingerprick of blood is taken and then placed onto the slide, the slide entered into the machine and after ten minutes a quantatitive results is given. This is importnat as there are tests out there that will say your PSA is over 4 (for instance), this test will actually give you a quantatitive figure. The PSAwatch has gone through many trials and studies and has been found to be equimolar to current tests. However when the manufacturer started to mass produce the slide, there were problems with accuracy. This is really why we are here now, the Company took the slide back in house and worked on it, they have also now got a new manufacturer to make the slide (higher capability to manufacture up to 2m units). The slide and manufacturer have now gone back through the CE approval process and have now come out with the regulatory approval for Europe. This is enough for it to be sold in other territories around the World, although places like the US, Japan and Chine will want to put the test and device through their own approval process. So there we are PSAwatch is as accurate as current testing in certain situations (for instance it cannot be used on patients who have had their Prostate removed as it doesn't offer the low end accuracy needed). But as a screening device it is as good as any other, it has the advantage of being point of care, in private Urology clinics it can be billed for by the physician and they don't have to pay a lab to do the bloodtest, it is easily used as a 2nd opinion. A Urologist told me he uses it on all his patients referred to him by GPs. The GP takes bloods and a high reading is obtained and the patient sent to a Urology clinic for follow up. PSA by it's nature can be skewed by physical exercise, recent sexual activity, infections, etc so when the patient arrives at his clinic he has a nurse do a PSAwatch test and this can sometimes mean the patient is told all is well and sent home. It is a great tool to have in this situation and can lead to much more comfortable patient visits (no horrible waiting or return visit to get your results) the resulst are there for the patient during his visit. I hope this helps, can I suggest you go onto the website and have a look at the PSAwatch video, it gives a very easily understood description of the testing procedure. All the best Trout.

Orbiter, the PSAwatch has yet to get approval for sale in the US and other territories, it also had problems with the manufacturing of the test slide consumable last year, this has now been rectified and a new manufacturer and slide has passed the regulatory process in Europe and now the Company and it's distribution partner Alere can work on marketing the test. It will still need to gain approval in the US and many Countries will want to conclude their own studies into the device and test before sales can take place. One large misconception is that Mediwatch is only about PSAwatch, it has sales of over £10m from other devices, consumables and services, it has launched several new products in the last few months and will be concentrating on it's mobile clinics and consumables more. Some of it's products are the Gold Standard, the Urodynamic devices and software are rated very highly and there is a large installed base of machines. So the reason for the drop was a profit warning last October (including the PSAwatch slide problem) and also a couple of larger holders have sold down their positions. The products aren't overhyped, the problem is that people haven't grasped that PSAwatch is still in the initial marketing and trial stage and until that has completed sales from the product will be negligible, they do expect to see more sales come through later this year. The Company is building up a one stop shop in Urology testing, it is also rolling out mobile clinics that will be able to go round to physicians offices, clinics, surgeries and perform a wide array of Urology tests, this will lead to cost savings for the physician and means more patients can be treated locally. Finally with an ageing population and getting larger, more and more people will need treatment for urological problems and MDW is amassing a suite of products to help.

Sorry, Tuesday not Monday.

Hi Knoxy, I am new to LSE, but I would say that the MDW ticker doesn't seem to get recognised for the streaming. I am surprised no-one has mentioned the results here. A question for you, did you buy 500k on Monday? at 2.9p?